Global Fibromyalgia Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Fibromyalgia treatment during 2019. Clinical development activities are being undertaken by more than 15 companies including Abide Therapeutics Inc, Aptinyx Inc, Astellas Pharma Inc, Cytocom Inc, FSD Pharma Inc and others.
A Significant contribution to the Fibromyalgia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Fibromyalgia pipeline included 17 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Fibromyalgia condition and increased access to investments is encouraging growth of Fibromyalgia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Fibromyalgia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Fibromyalgia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Fibromyalgia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Fibromyalgia. Further, orphan drug status, fast track designation, grants awarded and other special status for Fibromyalgia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Fibromyalgia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Fibromyalgia Pipeline candidates-
A Significant contribution to the Fibromyalgia pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Fibromyalgia pipeline included 17 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Fibromyalgia condition and increased access to investments is encouraging growth of Fibromyalgia drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Fibromyalgia drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Fibromyalgia therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Fibromyalgia pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Fibromyalgia. Further, orphan drug status, fast track designation, grants awarded and other special status for Fibromyalgia pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Fibromyalgia pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Fibromyalgia Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Fibromyalgia drugs
- Late phase: Phase 3 and in-approval Fibromyalgia drugs
- Company overview
- Snapshot
- Fibromyalgia therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Fibromyalgia- Disease Overview
2.2 Fibromyalgia- Pipeline Snapshot
2.3 Fibromyalgia- Pipeline Drugs by Phase
2.4 Fibromyalgia- Pipeline Drugs by Company
2.5 Fibromyalgia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abide Therapeutics Inc Fibromyalgia Drug Pipeline, H2- 2019
3.2 Aptinyx Inc Fibromyalgia Drug Pipeline, H2- 2019
3.3 Astellas Pharma Inc Fibromyalgia Drug Pipeline, H2- 2019
3.4 Cytocom Inc Fibromyalgia Drug Pipeline, H2- 2019
3.5 FSD Pharma Inc Fibromyalgia Drug Pipeline, H2- 2019
3.6 Grunenthal GmbH Fibromyalgia Drug Pipeline, H2- 2019
3.7 Innovative Med Concepts LLC Fibromyalgia Drug Pipeline, H2- 2019
3.8 Intec Pharma Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.9 Jiangsu Hengrui Medicine Co Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.10 Luye Pharma Group Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.11 Merck & Co Inc Fibromyalgia Drug Pipeline, H2- 2019
3.12 Mueller Medical International Fibromyalgia Drug Pipeline, H2- 2019
3.13 One World Cannabis Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.14 Pfizer Inc Fibromyalgia Drug Pipeline, H2- 2019
3.15 Tetra Bio-Pharma Inc Fibromyalgia Drug Pipeline, H2- 2019
3.16 Teva Pharmaceutical Industries Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.17 Vitality Biopharma Inc Fibromyalgia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Fibromyalgia- Phase 1 Drug Details
4.2 Fibromyalgia- Phase 1 Drug Overview
4.3 Fibromyalgia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Fibromyalgia- Phase 2 Drug Details
5.2 Fibromyalgia- Phase 2 Drug Overview
5.3 Fibromyalgia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Fibromyalgia- Phase 3 Drug Details
6.2 Fibromyalgia- Phase 3 Drug Overview
6.3 Fibromyalgia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Fibromyalgia- Pre-clinical Phase Drug Details
7.2 Fibromyalgia- Pre-clinical Phase Drug Overview
7.3 Fibromyalgia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Fibromyalgia- Disease Overview
2.2 Fibromyalgia- Pipeline Snapshot
2.3 Fibromyalgia- Pipeline Drugs by Phase
2.4 Fibromyalgia- Pipeline Drugs by Company
2.5 Fibromyalgia- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Abide Therapeutics Inc Fibromyalgia Drug Pipeline, H2- 2019
3.2 Aptinyx Inc Fibromyalgia Drug Pipeline, H2- 2019
3.3 Astellas Pharma Inc Fibromyalgia Drug Pipeline, H2- 2019
3.4 Cytocom Inc Fibromyalgia Drug Pipeline, H2- 2019
3.5 FSD Pharma Inc Fibromyalgia Drug Pipeline, H2- 2019
3.6 Grunenthal GmbH Fibromyalgia Drug Pipeline, H2- 2019
3.7 Innovative Med Concepts LLC Fibromyalgia Drug Pipeline, H2- 2019
3.8 Intec Pharma Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.9 Jiangsu Hengrui Medicine Co Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.10 Luye Pharma Group Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.11 Merck & Co Inc Fibromyalgia Drug Pipeline, H2- 2019
3.12 Mueller Medical International Fibromyalgia Drug Pipeline, H2- 2019
3.13 One World Cannabis Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.14 Pfizer Inc Fibromyalgia Drug Pipeline, H2- 2019
3.15 Tetra Bio-Pharma Inc Fibromyalgia Drug Pipeline, H2- 2019
3.16 Teva Pharmaceutical Industries Ltd Fibromyalgia Drug Pipeline, H2- 2019
3.17 Vitality Biopharma Inc Fibromyalgia Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Fibromyalgia- Phase 1 Drug Details
4.2 Fibromyalgia- Phase 1 Drug Overview
4.3 Fibromyalgia- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Fibromyalgia- Phase 2 Drug Details
5.2 Fibromyalgia- Phase 2 Drug Overview
5.3 Fibromyalgia- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Fibromyalgia- Phase 3 Drug Details
6.2 Fibromyalgia- Phase 3 Drug Overview
6.3 Fibromyalgia- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Fibromyalgia- Pre-clinical Phase Drug Details
7.2 Fibromyalgia- Pre-clinical Phase Drug Overview
7.3 Fibromyalgia- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
